b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31348981</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>08</Month>\n            <Day>20</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>08</Month>\n            <Day>20</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1879-0038</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>714</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Sep</Month>\n                        <Day>25</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Gene</Title>\n                <ISOAbbreviation>Gene</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>143997</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(19)30656-0</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2019.143997</ELocationID>\n            <Abstract>\n                <AbstractText>Based on Akt1 and Jak1 key roles in apoptosis and proliferation of many cancers, the aim of this study was to find a new gene therapy strategy by silencing of these main anti-apoptotic genes for HNSCC treatment. Cancerous HN5 and normal HUVEC cell lines were treated with Akt1 and Jak1 siRNAs alone or with each other combined with/without cisplatin. The MTS, flow cytometry, 4\',6-diamidino-2-phenylindole staining, real-time PCR and ELISA methods were utilized in this study. The highest percentage of apoptosis was observed in the treatment of Jak1 siRNA/cisplatin group in cancerous HN5 cells (96.5%) where this treatment showed 12.84% apoptosis in normal HUVEC cell line. Cell viability reduced significantly to 64.57% after treatment with Akt1 siRNA in HN5 treated group. Knocking down Akt1 and Jak1 genes using siRNAs could increase levels of apoptosis and reduce proliferation rate in HNSCC indicating the powerful effects of these genes siRNAs with or without chemotherapeutic agents in HNSCC treatment. In conclusion, the combination of siRNA-mediated gene-silencing strategy can be considered as a valuable and safe approach for sensitizing cancer cells to chemotherapeutic agents thus proposed further studies regarding this issue to approve some siRNA based therapeutics for using in clinic.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Vakili Saatloo</LastName>\n                    <ForeName>Maedeh</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Oral and Maxillofacial Department of Pathology, Faculty of Dentistry, Urmia Medical University, Urmia, West Azerbaijan, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Aghbali</LastName>\n                    <ForeName>Amir Ala</ForeName>\n                    <Initials>AA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Oral and Maxillofacial Department of Pathology, Faculty of Dentistry, Tabriz Medical University, Tabriz, East Azerbaijan, Iran. Electronic address: Aghbalia@tbzmed.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Koohsoltani</LastName>\n                    <ForeName>Maryam</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Oral and Maxillofacial Department of Pathology, Faculty of Dentistry, Tabriz Medical University, Tabriz, East Azerbaijan, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yari Khosroushahi</LastName>\n                    <ForeName>Ahmad</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: yarikhosroushahia@tbzmed.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>23</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Gene</MedlineTA>\n            <NlmUniqueID>7706761</NlmUniqueID>\n            <ISSNLinking>0378-1119</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.2</RegistryNumber>\n                <NameOfSubstance UI="C507904">JAK1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.2</RegistryNumber>\n                <NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>Q20Q21Q62J</RegistryNumber>\n                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053613" MajorTopicYN="N">Janus Kinase 1</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Akt1</Keyword>\n            <Keyword MajorTopicYN="N">Cell viability</Keyword>\n            <Keyword MajorTopicYN="N">Gene expression</Keyword>\n            <Keyword MajorTopicYN="N">Gene silencing</Keyword>\n            <Keyword MajorTopicYN="N">Gene therapy</Keyword>\n            <Keyword MajorTopicYN="N">Jak1</Keyword>\n            <Keyword MajorTopicYN="N">Protein level</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31348981</ArticleId>\n            <ArticleId IdType="pii">S0378-1119(19)30656-0</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.gene.2019.143997</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'